Paul C. Anderson
Technik-/Wissenschafts-/F&E-Leiter bei Inception IBD, Inc.
Profil
Paul C.
Anderson is currently the Chief Scientific Officer & Director at Inception IBD, Inc. He previously worked as the Director-Canadian Society of Chemistry at The Chemical Institute of Canada, Vice President-Chemistry at Ra Pharmaceuticals, Inc., and Vice President-Medicinal Chemistry at Syndexa Pharmaceuticals Corp.
He holds a doctorate degree from the University of Alberta and an undergraduate degree from the University of Western Ontario.
Aktive Positionen von Paul C. Anderson
| Unternehmen | Position | Beginn |
|---|---|---|
Inception IBD, Inc.
 Inception IBD, Inc. Miscellaneous Commercial ServicesCommercial Services Inception IBD, Inc. provides therapeutics services. It creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded by Eric Ogier-Denis, Yoram Bouhnik, Xavier Treton and Jacques Mizrahi in 2011 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 10.12.2015 |
Ehemalige bekannte Positionen von Paul C. Anderson
| Unternehmen | Position | Ende |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| The Chemical Institute of Canada | Corporate Officer/Principal | - |
Syndexa Pharmaceuticals Corp.
 Syndexa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Syndexa Pharmaceuticals Corp. developed novel medicines for the treatment and prevention of metabolic diseases. The company was founded in 2005 and was headquartered in Watertown, MA. | Corporate Officer/Principal | - |
Ausbildung von Paul C. Anderson
| University of Western Ontario | Undergraduate Degree |
| University of Alberta | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Syndexa Pharmaceuticals Corp.
Syndexa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Syndexa Pharmaceuticals Corp. developed novel medicines for the treatment and prevention of metabolic diseases. The company was founded in 2005 and was headquartered in Watertown, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
| The Chemical Institute of Canada | |
Inception IBD, Inc.
Inception IBD, Inc. Miscellaneous Commercial ServicesCommercial Services Inception IBD, Inc. provides therapeutics services. It creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded by Eric Ogier-Denis, Yoram Bouhnik, Xavier Treton and Jacques Mizrahi in 2011 and is headquartered in San Diego, CA. | Commercial Services |
